

Hande H Tuncer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1657356/publications.pdf>

Version: 2024-02-01

15
papers

370
citations

1478505

6
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

685
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
2	Umbilical Cord Mesenchymal Stem Cells Increase Expansion of Cord Blood Natural Killer Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1031-1038.	2.0	80
3	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
4	Outcomes of frontâ€line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	4.1	52
5	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
6	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	3.5	8
7	A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies. <i>Case Reports in Hematology</i> , 2018, 2018, 1-4.	0.4	2
8	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018, 132, 3142-3142.	1.4	2
9	<p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020, Volume 10, 1-5.	2.7	1
10	Ex-Vivo Expansion and mRNA Transfection of Cord Blood Derived Natural Killer Cells with Preserved Cytotoxicity.. <i>Blood</i> , 2006, 108, 3659-3659.	1.4	1
11	Mind It: Increasing Rate of Mental Health Disorders in Hospitalized Sickle Cell Patients. <i>Blood</i> , 2018, 132, 4689-4689.	1.4	1
12	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. <i>Blood</i> , 2018, 132, 4759-4759.	1.4	1
13	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6577-6577.	1.6	0
14	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. <i>Blood</i> , 2018, 132, 4410-4410.	1.4	0
15	Propensity Score Matched Analysis of Risk for Malignancies in Sickle Cell Anemia. <i>Blood</i> , 2018, 132, 5885-5885.	1.4	0